No Data
Protara Therapeutics Shares Are Trading Higher After the Company Announced It Will Review the Interim Data From Its Phase 2 ADVANCED-2 Trial.
Express News | Protara Therapeutics Shares Are Trading Higher After the Company Announced It Will Review the Interim Data From Its Phase 2 ADVANCED-2 Trial
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data From Phase 2 ADVANCED-2 Trial of TARA-002 in Patients With NMIBC on Monday, April 28, 2025
This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Scotiabank Initiates Protara Therapeutics(TARA.US) With Buy Rating, Announces Target Price $12
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday